Apogee Therapeutics (APGE) Competitors $44.32 +0.06 (+0.14%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$44.54 +0.22 (+0.51%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock APGE vs. VRNA, ROIV, ELAN, RVMD, LEGN, GRFS, TGTX, NUVL, LNTH, and TLXShould you be buying Apogee Therapeutics stock or one of its competitors? The main competitors of Apogee Therapeutics include Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), Lantheus (LNTH), and Telix Pharmaceuticals (TLX). These companies are all part of the "pharmaceutical products" industry. Apogee Therapeutics vs. Its Competitors Verona Pharma PLC American Depositary Share Roivant Sciences Elanco Animal Health Revolution Medicines Legend Biotech Grifols TG Therapeutics Nuvalent Lantheus Telix Pharmaceuticals Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) and Apogee Therapeutics (NASDAQ:APGE) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation. Do analysts recommend VRNA or APGE? Verona Pharma PLC American Depositary Share presently has a consensus price target of $107.36, indicating a potential upside of 19.19%. Apogee Therapeutics has a consensus price target of $95.80, indicating a potential upside of 116.16%. Given Apogee Therapeutics' higher possible upside, analysts plainly believe Apogee Therapeutics is more favorable than Verona Pharma PLC American Depositary Share.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verona Pharma PLC American Depositary Share 0 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 3.00Apogee Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in VRNA or APGE? 85.9% of Verona Pharma PLC American Depositary Share shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 4.8% of Verona Pharma PLC American Depositary Share shares are held by company insiders. Comparatively, 42.8% of Apogee Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better earnings & valuation, VRNA or APGE? Verona Pharma PLC American Depositary Share has higher revenue and earnings than Apogee Therapeutics. Verona Pharma PLC American Depositary Share is trading at a lower price-to-earnings ratio than Apogee Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerona Pharma PLC American Depositary Share$42.28M181.37-$173.42M-$2.00-45.04Apogee TherapeuticsN/AN/A-$182.15M-$3.60-12.31 Which has more volatility & risk, VRNA or APGE? Verona Pharma PLC American Depositary Share has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500. Comparatively, Apogee Therapeutics has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Does the media refer more to VRNA or APGE? In the previous week, Verona Pharma PLC American Depositary Share and Verona Pharma PLC American Depositary Share both had 3 articles in the media. Verona Pharma PLC American Depositary Share's average media sentiment score of 1.34 beat Apogee Therapeutics' score of 0.62 indicating that Verona Pharma PLC American Depositary Share is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verona Pharma PLC American Depositary Share 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apogee Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is VRNA or APGE more profitable? Apogee Therapeutics' return on equity of -28.35% beat Verona Pharma PLC American Depositary Share's return on equity.Company Net Margins Return on Equity Return on Assets Verona Pharma PLC American Depositary ShareN/A -69.65% -28.00% Apogee Therapeutics N/A -28.35%-26.98% SummaryVerona Pharma PLC American Depositary Share and Apogee Therapeutics tied by winning 6 of the 12 factors compared between the two stocks. Get Apogee Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APGE vs. The Competition Export to ExcelMetricApogee TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.04B$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-12.3121.3126.1719.90Price / SalesN/A278.47413.55113.66Price / CashN/A41.4736.1356.90Price / Book2.787.518.025.38Net Income-$182.15M-$55.05M$3.15B$248.50M7 Day Performance1.16%2.07%1.48%2.06%1 Month Performance19.53%4.84%3.66%4.86%1 Year Performance18.19%5.37%34.68%20.24% Apogee Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APGEApogee Therapeutics2.7243 of 5 stars$44.32+0.1%$95.80+116.2%+16.0%$2.04BN/A-12.3191Analyst ForecastHigh Trading VolumeVRNAVerona Pharma PLC American Depositary Share2.5901 of 5 stars$94.58+0.8%$101.10+6.9%+482.7%$7.99B$42.28M-47.2930Positive NewsAnalyst ForecastROIVRoivant Sciences1.9443 of 5 stars$11.27-1.1%$17.50+55.3%+3.9%$7.74B$29.05M-45.08860ELANElanco Animal Health2.3429 of 5 stars$14.29flat$15.17+6.1%+5.1%$7.10B$4.44B19.319,000Analyst ForecastRVMDRevolution Medicines4.4993 of 5 stars$36.79-0.3%$67.58+83.7%-0.5%$6.88B$11.58M-9.20250Analyst RevisionLEGNLegend Biotech3.4951 of 5 stars$35.49+2.5%$76.20+114.7%-19.7%$6.36B$627.24M-60.152,609News CoveragePositive NewsAnalyst ForecastGRFSGrifols4.137 of 5 stars$9.04+2.0%$10.30+13.9%+40.2%$6.09B$7.81B7.7323,822TGTXTG Therapeutics3.7706 of 5 stars$35.99-2.0%$40.80+13.4%+98.2%$5.83B$329M149.96290NUVLNuvalent3.736 of 5 stars$76.30-4.2%$119.60+56.7%+10.3%$5.72BN/A-17.3840Analyst UpgradeInsider TradeLNTHLantheus4.4515 of 5 stars$81.86+0.5%$130.50+59.4%+1.4%$5.64B$1.53B23.26700Positive NewsTLXTelix PharmaceuticalsN/A$16.07+0.4%$22.00+36.9%N/A$5.41B$516.72M0.00N/AGap Down Related Companies and Tools Related Companies VRNA Competitors ROIV Competitors ELAN Competitors RVMD Competitors LEGN Competitors GRFS Competitors TGTX Competitors NUVL Competitors LNTH Competitors TLX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APGE) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apogee Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apogee Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
